Universal influenza virus vaccines and therapeutics: where do we stand with influenza B virus?
- 1 August 2018
- journal article
- review article
- Published by Elsevier BV in Current Opinion in Immunology
- Vol. 53, 45-50
- https://doi.org/10.1016/j.coi.2018.04.002
Abstract
No abstract availableKeywords
Funding Information
- NIAID (R01 AI117287)
- NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) (HHSN272201400008C)
This publication has 37 references indexed in Scilit:
- Influenza Virus Surveillance in Pakistan during 2008-2011PLOS ONE, 2013
- A monoclonal antibody targeting a highly conserved epitope in influenza B neuraminidase provides protection against drug resistant strainsBiochemical and Biophysical Research Communications, 2013
- The Burden of Influenza B: A Structured Literature ReviewAmerican Journal of Public Health, 2013
- Human Monoclonal Antibodies Broadly Neutralizing against Influenza B VirusPLoS Pathogens, 2013
- Influenza B Lineage Circulation and Hospitalization Rates in a Subtropical City, Hong Kong, 2000–2010Clinical Infectious Diseases, 2012
- Highly Conserved Protective Epitopes on Influenza B VirusesScience, 2012
- Surveillance of Influenza in Indonesia, 2003-2007Influenza and Other Respiratory Viruses, 2012
- Universal Influenza B Vaccine Based on the Maturational Cleavage Site of the Hemagglutinin PrecursorJournal of Virology, 2005
- Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderlyJournal of Medical Virology, 2000
- A New Type of Virus from Epidemic InfluenzaScience, 1940